PMC 12190491
10 Recently, several clinical trials have shown the potential effects of these medications in not only in glycemic control but also in the improvement of cardiovascular outcomes, weight loss, osteoarthritis, 11 metabolic dysfunctionassociated steatohepatitis (MASH), 12 Parkinsons disease, 13 chronic kidney disease (CKD) 14 and obstructive sleep apnea
Phase 3 trials are underway, and a realistic approval window is late 2026 at the earliest, more likely 2027
J Clin Endocrinol Metab (2008) 93:26708
Contrave , a daily oral medication, is another FDA-approved prescription that can help support weight loss
Trends in first-time prescribing First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in December 2025 decreased, relative to September 2025 (-6.6%)